MX2022003346A - Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. - Google Patents

Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro.

Info

Publication number
MX2022003346A
MX2022003346A MX2022003346A MX2022003346A MX2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A
Authority
MX
Mexico
Prior art keywords
dosage forms
bupropion
enantiomerically enriched
methods
pure
Prior art date
Application number
MX2022003346A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/052210 external-priority patent/WO2020061486A2/en
Priority claimed from US16/830,637 external-priority patent/US20200222339A1/en
Priority claimed from US16/907,691 external-priority patent/US11433035B2/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MX2022003346A publication Critical patent/MX2022003346A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta divulgación se refiere a las formas de dosificación que contienen un bupropión enantioméricamente enriquecido o puro, tal como un exceso enantiomérico del (S)-bupropión, del (S)-bupropión enantioméricamente enriquecido o del (S)-bupropión enantioméricamente puro, y a los métodos de uso de estas formas de dosificación. Estas formas de dosificación se pueden administrar a los seres humanos en una cantidad reducida en comparación con la cantidad de bupropión racémico que se administraría en la misma situación.
MX2022003346A 2019-09-20 2020-08-18 Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. MX2022003346A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2019/052210 WO2020061486A2 (en) 2018-09-20 2019-09-20 Dosage forms and methods for enantiomerically enriched or pure bupropion
US202062971174P 2020-02-06 2020-02-06
US202062978626P 2020-02-19 2020-02-19
US202062992060P 2020-03-19 2020-03-19
US16/830,637 US20200222339A1 (en) 2018-09-20 2020-03-26 Dosage forms and methods for enantiomerically enriched or pure bupropion
US16/907,691 US11433035B2 (en) 2018-09-20 2020-06-22 Dosage forms and methods for enantiomerically enriched or pure bupropion
PCT/US2020/046755 WO2021055124A1 (en) 2019-09-20 2020-08-18 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
MX2022003346A true MX2022003346A (es) 2022-04-11

Family

ID=74884634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003346A MX2022003346A (es) 2019-09-20 2020-08-18 Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro.

Country Status (14)

Country Link
EP (1) EP4031121A4 (es)
JP (2) JP2022549192A (es)
KR (1) KR20220066930A (es)
CN (1) CN114423417A (es)
AU (2) AU2020349419B2 (es)
BR (1) BR112022005045A2 (es)
CA (1) CA3154718A1 (es)
CO (1) CO2022003126A2 (es)
CR (1) CR20220119A (es)
EC (1) ECSP22030119A (es)
IL (1) IL291514A (es)
MX (1) MX2022003346A (es)
PE (1) PE20221314A1 (es)
WO (1) WO2021055124A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318960A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US20190216800A1 (en) * 2013-11-05 2019-07-18 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2013014166A (es) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Enantiomeros activos y sus sales para el tratamiento de la obesidad.
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Pure Buporfion Dosage Forms and Methods for Enantimeric Distortion Targets

Also Published As

Publication number Publication date
CA3154718A1 (en) 2021-03-25
AU2024200081A1 (en) 2024-01-25
ECSP22030119A (es) 2022-05-31
CR20220119A (es) 2022-06-22
BR112022005045A2 (pt) 2022-07-05
KR20220066930A (ko) 2022-05-24
CN114423417A (zh) 2022-04-29
PE20221314A1 (es) 2022-09-07
EP4031121A4 (en) 2022-11-30
AU2020349419B2 (en) 2023-11-02
WO2021055124A1 (en) 2021-03-25
EP4031121A1 (en) 2022-07-27
AU2020349419A1 (en) 2022-03-24
CO2022003126A2 (es) 2022-04-19
IL291514A (en) 2022-05-01
JP2024059812A (ja) 2024-05-01
JP2022549192A (ja) 2022-11-24

Similar Documents

Publication Publication Date Title
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
ZA202110659B (en) Methods of reducing the risk of cardiovascular events in a subject
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
GEP20247585B (en) Furoindazole derivatives
IL276871A (en) Pure bupropion dosage forms and methods for enantiomeric distortion purposes
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2021007142A (es) Compuestos organicos.
MX2022003346A (es) Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
EP3818981A4 (en) SYNERGIC PHARMACEUTICAL COMBINATION OF THE ACTIVE ENANTIOMER S-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2018013324A (es) Métodos y composiciones para el tratamiento del síndrome de rett.
PH12021500016A1 (en) Methods of reducing the risk of cardiovascular events in a subject
EA202191907A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
AU2017202335A1 (en) Hangover cure.
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα
UA108990C2 (en) THE APPLICATION OF 4-AMINO-PIRIDIN NORRELIVER IN CREATIVE CREATIVES IN CANCER CANCER
UA27828U (en) Method for treating prosthetic stomatitis against the background metabolic syndrome
UA27830U (en) Method for treating prosthetic stomatitis against the background of metabolic syndrome